MedTrace Logo

Environmental Tobacco Smoke Exposure Reduction in High-Risk Preteens

NCT00217893 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 203

Last updated 2013-10-24

No results posted yet for this study

Summary

This study will determine the effect of combining counseling, urine cotinine feedback, and incentives in reducing environmental tobacco smoke (ETS) exposure and susceptibility to smoking among high-risk preteens.

Conditions

Interventions

BEHAVIORAL

Counseling

One-on-one behavioral counseling with pre-teen child; 8 to 10 weekly or bi-weekly sessions; focus on identifying sources of exposure to ETS and means to avoid exposure; goal-setting, role-playing, monitoring progress, feedback includes reported info and urine cotinine level.

BEHAVIORAL

Urine Cotinine Feedback

Urine collected from child at each weekly/bi-weekly counseling session; cotinine level discussed at subsequent session.

BEHAVIORAL

Contingent Incentives

Child earns small prizes for on-task behavior in sessions, plus earns tokens redeemable for other prizes based on reduction in ETS exposure (reported and cotinine level).

BEHAVIORAL

Usual education program

Participants will receive the usual education about ETS.

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • San Diego State University

    lead OTHER

Principal Investigators

  • Melbourne F. Hovell · San Diego State University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
8 Years
Max Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-02-28
Primary Completion
2008-01-31
Completion
2008-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00217893 on ClinicalTrials.gov